Enanta Pharmaceuticals, Inc.
corporate_fare Company Profile
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ENTA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ENTA spans 10-K, 8-K, 10-Q, 424B5.
Recent high-impact activity:
- Enanta 10-K: $68.2M FY26 Loss, $194.5M Cash Funds Operations Into Fiscal 2029
- Enanta Posts $23.7M Q4 Loss, Cuts Workforce by a Third, Cash Through Fiscal 2029
- Enanta Posts 81-Cent Quarterly Loss as Patent Setback Clouds Pipeline
- UPC Invalidates Enanta's '265 Patent; Paxlovid Infringement Action Unfounded
- Enanta CEO Jay Luly to Retire by February 1, 2027; Tara Kieffer Named COO
Financial Snapshot
Short Interest & Short Volume
7.63 days to coverFINRA reported short interest of 1,856,510 shares in ENTA as of the October 30, 2026 settlement, a 18.0% decrease from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 69.4% of ENTA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for ENTA, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.
New At-The-Market Offering Established · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →